Literature DB >> 28854423

Nonampullary Duodenal Adenomas Rarely Recur after Complete Endoscopic Resection: A Swiss Experience Including a Literature Review.

Piero V Valli1, Joachim C Mertens, Amnon Sonnenberg, Peter Bauerfeind.   

Abstract

INTRODUCTION: Duodenal polyps and especially duodenal adenomas are a rare and mostly coincidental finding in patients undergoing upper gastrointestinal endoscopy. Due to their malignant potential, duodenal adenomas should be removed upon diagnosis. So far, the limited available data on the performance of endoscopic polypectomy show conflicting results with regard to adverse events and the adenoma recurrence rate. PATIENTS AND METHODS: After summarizing the currently available data, we retrospectively analyzed all patients undergoing endoscopic resection of nonampullary duodenal adenomas (NAD) at our institution between 2006 and 2016.
RESULTS: A total of 78 patients underwent endoscopic polypectomy for NAD adenoma. End-of-treatment success with complete resection requiring a mean of 1.2 interventions was achieved in 91% (n = 71). Procedural hemorrhage occurred in 12.8% (n = 10), whereas delayed bleeding was noted in 9% (n = 7). Duodenal perforation was registered and successfully treated in 2 cases (2.6%). No adenoma recurrence was noted following primary complete adenoma resection after a mean follow-up time of 33 months. Acute post-polypectomy bleeding was statistically significantly associated with large polyp size (p = 0.003) and lack of endoscopic prophylaxis (p = 0.0008). Delayed post-polypectomy bleeding showed a trend in the occurrence of large polyps (p = 0.064), and was statistically significantly associated with familial cancer syndrome (p = 0.019) and advanced histopathology (p = 0.013).
CONCLUSION: Our data suggest that endoscopic polypectomy of NAD is well feasible with high success rates. Procedural and delayed hemorrhage seems to be the primary issue rather than adenoma recurrence. We therefore advocate referral of patients with large NAD to experienced centers for endoscopic resection.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Duodenal adenoma; Duodenal polyposis; Endoscopic resection; Endoscopic treatment; Nonampullary duodenal adenoma

Mesh:

Year:  2017        PMID: 28854423     DOI: 10.1159/000479625

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  5 in total

Review 1.  Clinical practice guidelines for duodenal cancer 2021.

Authors:  Kenji Nakagawa; Masayuki Sho; Mitsuhiro Fujishiro; Naomi Kakushima; Takahiro Horimatsu; Ken-Ichi Okada; Mikitaka Iguchi; Toshio Uraoka; Motohiko Kato; Yorimasa Yamamoto; Toru Aoyama; Takahiro Akahori; Hidetoshi Eguchi; Shingo Kanaji; Kengo Kanetaka; Shinji Kuroda; Yuichi Nagakawa; Souya Nunobe; Ryota Higuchi; Tsutomu Fujii; Hiroharu Yamashita; Suguru Yamada; Yukiya Narita; Yoshitaka Honma; Kei Muro; Tetsuo Ushiku; Yasuo Ejima; Hiroki Yamaue; Yasuhiro Kodera
Journal:  J Gastroenterol       Date:  2022-10-19       Impact factor: 6.772

2.  Risk Factors of Non-en Bloc Resection and Non-R0 Resection During Endoscopic Resection in the Treatment of Superficial Duodenal Epithelial Lesions.

Authors:  Shifeng Fu; Jian Gong; Mei Zhou; Yongjun Wang; Deliang Liu; Yuyong Tan
Journal:  Front Oncol       Date:  2022-05-20       Impact factor: 5.738

Review 3.  Endoscopic resection of superficial non-ampullary duodenal epithelial tumor.

Authors:  Motohiko Kato; Takanori Kanai; Naohisa Yahagi
Journal:  DEN open       Date:  2021-09-05

Review 4.  Endoscopic management of duodenal adenomatosis in familial adenomatous polyposis-A case-based review.

Authors:  E Soons; T M Bisseling; M C A van Kouwen; G Möslein; P D Siersema
Journal:  United European Gastroenterol J       Date:  2021-05-07       Impact factor: 4.623

Review 5.  Endoscopic management of non-ampullary duodenal adenomas.

Authors:  Maxime Amoyel; Arthur Belle; Marion Dhooge; Einas Abou Ali; Rachel Hallit; Frederic Prat; Anthony Dohan; Benoit Terris; Stanislas Chaussade; Romain Coriat; Maximilien Barret
Journal:  Endosc Int Open       Date:  2022-01-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.